Business Wire

ZCUBE

9.6.2020 08:02:10 CEST | Business Wire | Press release

Share
Zcube: Digital Health, Open Accelerator Is Seeking Innovators to Shape the Future of Health

Zcube, Zambon Research Venture, has launched the fourth edition of Open Accelerator , the international acceleration programme dedicated to startups in the Life Sciences, which seeks to identify and accelerate the best solutions that will shape the future of health. The 2020 Call, focused on digital solutions, is running until the 20th of July. Candidates can apply on the website www.openaccelerator.it

Open Accelerator is looking for innovative, high-tech projects and startups leveraging digital technologies to improve patients’ lives . The best proposals will take part in the acceleration program with the possibility of receiving a seed investment of up to € 100,000 per project.

The 2020 Call for Solutions is preferably targeted at the therapeutic areas of the Central Nervous System and Respiratory, with a particular focus on the 4 technological macro areas: Digital Prevention, Monitoring and Therapeutics; Digital Diagnostics; Virtual Health; Clinical Trials Digitalization.

This year, in an attempt to transform the COVID-19 emergency into a growth opportunity for the healthcare system, ZCube is also presenting the Special Challenge concerning new ways of interaction among healthcare professionals, Industry and the community.

“Open Accelerator is continuing with conviction into its fourth edition, reaffirming its commitment to supporting young startups, helping to transform promising projects into concrete solutions for patients” – comments Elena Zambon, President of Zambon Spa and creator of the accelerator programme – “Digital solutions have never been such a vital support for patients and caregivers as they have at this time. We have direct experience of this through ParkinsonCare, our telenursing service with a human touch. That is why we have decided to dedicate the 2020 Call to digital initiatives. We are convinced that they will be increasingly important in tackling the challenges that lie ahead in terms of health and the system's sustainability. This programme is yet another way in which we are pursuing with conviction our commitment to improving patients' lives, integrating cure and care with a multidisciplinary approach”.

After the closure of the Call, on the 20th of July, the Open Accelerator team in collaboration with a panel of experts will select the startups which between October and November will participate in the intensive 4-week acceleration programme , consisting of tailored online and onsite sessions held in the OpenZone scientific campus just outside Milan .

By taking part in the Open Accelerator programme, the startups will have access to a vast international network of entrepreneurs, scientists, investors, Venture capitalists and Life Sciences professionals. At the end of the programme the most promising projects will be awarded a seed investment of up to € 100,000 . Finally, any possible synergies with the companies of the Zambon Group will be assessed.

Open Accelerator 2020 Call is one of a kind both- for its focus on digital health technologies and for its pragmatic approach, strongly focused on identifying concrete proposals for delivering solutions to healthcare needs ” - says Fabrizio Conicella, General Manager and Board Member of OpenZone and Zcube - “It is only through the active engagement of existing and prospective partnerships that we will be able to maximize the potential of the proposals we receive and select with a clear objective: to offer to the market innovative solutions that currently don't exist ”.

The initiative also leverages the support of several partners, including Deloitte, Unicredit Start Lab, Premio Marzotto, IQVIA Biotech, Italian Angels for Biotech, Portolano & Cavallo, Bird&Bird, Innogest, Evoleen, HUMA, NINA Capital, and Lifeseeder. Discussions are currently underway with other potential Italian and international partners.

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Andersen Consulting tilføjer House of Code for at styrke teknologi- og dataløsninger26.6.2026 20:01:00 CEST | Pressemeddelelse

Andersen Consulting forstærker sine kompetencer inden for teknologisk transformation gennem en samarbejdsaftale med House of Code, en global virksomhed med hovedkvarter i USA, der specialiserer sig i datadrevne platforme, automatisering og agentbaserede ai-løsninger. House of Code blev stiftet i 2001 og udvikler softwareløsninger samt yder rådgivning til energihandels- og finanssektoren med kunder, der spænder over hedgefonde, kapitalfonde og forsyningsvirksomheder. Virksomheden besidder dyb ekspertise inden for energihandel og risikostyring og hjælper organisationer med systemimplementering, forretningstransformation, dataautomatisering og ai-underbygget modernisering af arbejdsgange. Deres proprietære platform, Enterprise Platform for Integrated Compliance (EPIC), skaber en mere effektiv datastyring, automatiserer rapporteringsprocesser, forbedrer den driftsmæssige gennemsigtighed på tværs af virksomhedssystemer og skaber et fundament for opbygning af intelligente, agentbaserede arbe

Capco Recognized by OpenAI for Innovation and Responsible AI Leadership26.6.2026 20:00:00 CEST | Press release

Receives AI Governance & Risk Excellence Award at OpenAI Partner SummitCapco’s UK AI Lab wins OpenAI Codex Hackathon Global management and technology consultancy Capco, a Wipro company,has been recognized by OpenAI for both AI innovation and responsible AI leadership. Capco received the AI Governance & Risk Excellence Award at the recent OpenAI Partner Summit 2026 in San Francisco, highlighting Capco’s ability to deliver enterprise-grade AI outcomes in highly regulated environments. The award recognizes Capco’s expert advantage when helping financial services and energy organizations to scale AI with confidence, balancing innovation with strong governance to reduce risk, strengthen compliance and improve customer outcomes. This award follows Capco winning the OpenAI Codex Hackathon, where its UK AI Lab competed against more than 30 teams and over 100 participants from across the OpenAI partner ecosystem. Capco's winning entry Sentra – a consulting-led, AI-powered retail banking solutio

Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release

If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids

Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release

Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use

DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release

-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye